Related Experiment Video

Updated: Jun 6, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Autonomic and metabolic effects of OSA in childhood obesity

F M Oliveira1, W H Tran, D Lesser

  • 1University of Southern California, Department of Biomedical Engineering, DRB 140, Los Angeles, CA 90089, USA. foliveir@usc.edu

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
|November 25, 2010
PubMed

Insights

Intermittent hypoxia from obstructive sleep apnea (OSA) in obese children independently worsens insulin resistance and autonomic dysfunction. This impacts cardiovascular health and metabolic function in affected youth.

Area of Science:

  • Pediatric Endocrinology
  • Sleep Medicine
  • Cardiovascular Physiology

Background:

  • Obesity and obstructive sleep apnea (OSA) are prevalent in children.
  • OSA is associated with metabolic and cardiovascular complications.
  • The specific impact of intermittent hypoxia in pediatric OSA on autonomic control and metabolism requires further elucidation.

Purpose of the Study:

  • To investigate the effects of intermittent hypoxia exposure on cardiovascular autonomic control.
  • To assess the impact on metabolic function in obese children with OSA.
  • To determine the independent contribution of intermittent hypoxia to these dysfunctions.

Main Methods:

  • Polysomnography to assess sleep parameters.
  • FSIVGTT and fasting blood samples for metabolic assessment.
  • Noninvasive monitoring of respiration, blood pressure, and heart rate variability; DEXA scans for adiposity.

Main Results:

  • Intermittent hypoxia in pediatric OSA independently contributes to insulin resistance.
  • Autonomic dysfunction was observed in overweight children with OSA.
  • Specific sleep and cardiovascular variability parameters were deduced from measurements.

Conclusions:

  • Intermittent hypoxia is a significant independent factor in the development of insulin resistance in obese children with OSA.
  • OSA-related intermittent hypoxia contributes to autonomic dysfunction in this population.
  • Findings highlight the critical link between sleep-disordered breathing, metabolic health, and cardiovascular regulation in pediatric obesity.

More Related Videos

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

Experimental Approach to Examine Leptin Signaling in the Carotid Bodies and its Effects on Control of Breathing05:45

Experimental Approach to Examine Leptin Signaling in the Carotid Bodies and its Effects on Control of Breathing

Published on: October 25, 2019

Related Concept Videos

Sleep Apnea01:21

Sleep Apnea

Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.